Citigroup Inc. Reiterates Sell Rating for St. Jude Medical (STJ)
St. Jude Medical (NYSE:STJ)‘s stock had its “sell” rating restated by stock analysts at Citigroup Inc. in a report issued on Monday, Analyst RN reports. They currently have a $53.00 target price on the stock. Citigroup Inc.’s price objective points to a potential downside of 20.25% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of St. Jude Medical in a research note on Thursday, April 17th. They now have a $78.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of St. Jude Medical in a research note on Thursday, April 17th. They now have a $64.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of St. Jude Medical in a research note on Thursday, April 17th. They now have a $74.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $61.74.
Shares of St. Jude Medical (NYSE:STJ) traded up 0.51% on Monday, hitting $62.94. The stock had a trading volume of 2,229,964 shares. St. Jude Medical has a 1-year low of $40.55 and a 1-year high of $68.79. The stock’s 50-day moving average is $65.22 and its 200-day moving average is $61.80. The company has a market cap of $18.208 billion and a P/E ratio of 24.36.
St. Jude Medical (NYSE:STJ) last issued its quarterly earnings data on Wednesday, April 16th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.01. The company had revenue of $1.36 million for the quarter, compared to the consensus estimate of $1.36 million. During the same quarter in the previous year, the company posted $0.92 earnings per share. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts expect that St. Jude Medical will post $3.99 EPS for the current fiscal year.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.